Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution?
ABSTRACT Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor and has been approved for the treatment of patients with Ph + chronic myelogenous leukemia. Bosutinib is a substrate of P‐glycoprotein (P‐gp) in vitro and is predominantly metabolized by CYP3A4 in humans with minimal urinary...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wiley
2026-01-01
|
| Серии: | CPT: Pharmacometrics & Systems Pharmacology |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/psp4.70179 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|